Man Group
MGX icon

Man Group’s Metagenomi Therapeutics MGX Stock Holding History

Man Group’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$105K Buy
78,636
+22,139
+39% +$34.4K ﹤0.01% 2347
2025
Q4 		$91.5K Buy
56,497
+3,609
+7% +$7.81K ﹤0.01% 2206
2025
Q3 		$125K Buy
+52,888
New +$107K ﹤0.01% 2144

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Man Group's MGX Position: Q1 2026 in Review

Man Group increased its Metagenomi Therapeutics (MGX) stake by 39% in Q1 2026, buying an estimated $34.4K and bringing the position to 78,636 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #2347.

Man Group first reported a position in MGX in Q3 2025 and has held it in 3 quarters since. The position peaked at $125K in Q3 2025. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • Man Group held 78,636 shares of Metagenomi Therapeutics worth $105K as of Q1 2026.
  • Man Group bought 22,139 Metagenomi Therapeutics shares in Q1 2026, an estimated $34.4K.
  • Metagenomi Therapeutics made up ﹤0.01% of Man Group's portfolio in Q1 2026, its #2347 holding.
  • Man Group first reported a position in Metagenomi Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Man Group's Metagenomi Therapeutics position peaked at $125K in Q3 2025.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.